- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04720183
Drug-drug Interaction Study With GLPG3970 and Sulfasalazine in Adult, Healthy Subjects
July 13, 2021 updated by: Galapagos NV
A Phase 1, Fixed Sequence, Open-label, Drug-drug Interaction Study to Evaluate the Effect of GLPG3970 on the Pharmacokinetics of Sulfasalazine in Adult, Healthy Subjects
GLPG3970 will be given with sulfasalazine to investigate the effect of co-administration on the pharmacokinetics of sulfasalazine, and on the safety and tolerability of the drugs in healthy adult subjects.
Study Overview
Study Type
Interventional
Enrollment (Actual)
8
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
New Jersey
-
Newark, New Jersey, United States, 07103
- Biotral Inc
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male or female between 18 and 55 years of age (extremes included), on the date of signing the informed consent form (ICF). Females should be of non-childbearing potential.
- A body mass index (BMI) between 18.0 to 30.0 kg/m2, inclusive.
- A breast cancer resistance protein (BCRP) c421C/C genotype.
- Judged to be in good health by the investigator based upon the results of a medical history, physical examination, vital signs, 12-lead electrocardiogram (ECG), and fasting clinical laboratory safety tests, available at screening and prior to the first sulfasalazine administration. Bilirubin, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) must be no greater than 1.5x upper limit of normal range (ULN). Other clinical laboratory safety test results must be within the reference ranges or test results that are outside the reference ranges need to be considered not clinically significant in the opinion of the investigator.
This list only contains the key inclusion criteria.
Exclusion Criteria:
- Known hypersensitivity to the investigational product (IP) (GLPG3970), or sulfasalazine, or sulfa drugs, or to their ingredients, or history of a significant allergic reaction to IP or sulfasalazine ingredients as determined by the investigator.
- Positive serology for hepatitis B virus surface antigen (HBsAg) or hepatitis C virus (HCV) or history of hepatitis from any cause with the exception of hepatitis A that was resolved at least 3 months prior to first dosing of sulfasalazine.
- History of or a current immunosuppressive condition (e.g. human immunodeficiency virus (HIV) infection).
- Having any illness, judged by the investigator as clinically significant, in the 3 months prior to first dosing of sulfasalazine.
- Presence or sequelae of gastrointestinal, liver, kidney (estimated glomerular filtration rate (eGFR) <=90 mL/min/1.73 m2, using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula) or other conditions known to interfere with the absorption, distribution, metabolism, or excretion of drugs.
- Subjects with an N-acetyltransferase 2 (NAT2) slow acetylator genotype.
This list only contains the key exclusion criteria.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Sulfasalazine + GLPG3970
|
On Day 1, Day 5 and Day 9, a single oral dose of sulfasalazine tablets in fasted state.
On Day 5 and Day 9, a single dose of GLPG3970 oral solution in fasted state.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Maximum observed concentration (Cmax) of sulfasalazine
Time Frame: Between Day 1 pre-dose and Day 12
|
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
|
Between Day 1 pre-dose and Day 12
|
Cmax of sulfapyridine
Time Frame: Between Day 1 pre-dose and Day 12
|
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
|
Between Day 1 pre-dose and Day 12
|
Area under the plasma concentration-time curve from time zero to infinity (AUC0-inf) of sulfasalazine
Time Frame: Between Day 1 pre-dose and Day 12
|
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
|
Between Day 1 pre-dose and Day 12
|
AUC0-inf of sulfapyridine
Time Frame: Between Day 1 pre-dose and Day 12
|
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
|
Between Day 1 pre-dose and Day 12
|
Sulfapyridine to sulfasalazine AUC ratio
Time Frame: Between Day 1 pre-dose and Day 12
|
To evaluate the effect of GLPG3970 on the pharmacokinetics (PK) of sulfasalazine and its active metabolite sulfapyridine in healthy subjects.
|
Between Day 1 pre-dose and Day 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
Time Frame: From Day 1 through study completion, an average of 1 month
|
To evaluate the safety and tolerability of the coadministration of GLPG3970 with sulfasalazine in healthy subjects
|
From Day 1 through study completion, an average of 1 month
|
Maximum observed concentration (Cmax) of GLPG3970
Time Frame: Between Day 5 pre-dose and Day 10
|
To evaluate the PK of GLPG3970 in presence of sulfasalazine in healthy subjects
|
Between Day 5 pre-dose and Day 10
|
Area under the plasma concentration-time curve from time zero till the last observed quantifiable concentration (AUC0-t)
Time Frame: Between Day 5 pre-dose and Day 10
|
To evaluate the PK of GLPG3970 in presence of sulfasalazine in healthy subjects
|
Between Day 5 pre-dose and Day 10
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Natalia Rueda-Rincon, MD, Galapagos NV
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 11, 2021
Primary Completion (Actual)
April 21, 2021
Study Completion (Actual)
April 23, 2021
Study Registration Dates
First Submitted
January 19, 2021
First Submitted That Met QC Criteria
January 19, 2021
First Posted (Actual)
January 22, 2021
Study Record Updates
Last Update Posted (Actual)
July 14, 2021
Last Update Submitted That Met QC Criteria
July 13, 2021
Last Verified
July 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- GLPG3970-CL-117
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Sulfasalazine
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedDiarrhea | Unspecified Adult Solid Tumor, Protocol Specific | Gastrointestinal ComplicationsUnited States
-
Qiong FuNot yet recruiting
-
The Second Affiliated Hospital of Chongqing Medical...RecruitingFibrosis, Liver | Cirrhosis, LiverChina
-
Karolinska InstitutetHarvard Medical School (HMS and HSDM)Completed
-
Chung Shan Medical UniversityUnknownAnkylosing SpondylitisTaiwan
-
Infectious Diseases Physicians, Inc.Johns Hopkins UniversityCompletedProsthetic Joint Infection | Osteomyelitis | Septic Arthritis | Bone Infection | Joint InfectionUnited States
-
Cairo UniversityActive, not recruitingOral Lichen Planus | Corticosteroids | Topical SulfasalazineEgypt
-
University of NebraskaCompletedRheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingAcute Myeloid LeukemiaFrance
-
Singapore General HospitalTerminatedRheumatoid ArthritisSingapore